Factors determining effectiveness of interferons in managing hepatitis C: New targets and new approaches

International Journal of Interferon, Cytokine and Mediator Research

Volumn 2, Issue 1, 2010, Pages 85-95

  Rajoriya, N ^a   Barnes, Eleanor ^a,b  

^a Department of Pathogen Research ^*  (United Kingdom)

^b NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

Hepatitis C virus; Interferon; Interferon ; Novel interferons; Pharmacodynamics; Ribavirin

Indexed keywords

ALBINTERFERON; ALPHA INTERFERON; ANTIVIRUS AGENT; BELEROFON; BLX 883; BOCEPRAVIR; CORE PROTEIN; CYCLOPHILIN INHIBITOR; ENVELOPE PROTEIN; INTERFERON; ITMN 191; LOCTERON; MAXY ALPHA; OMEGA INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; R 7025; R 7128; RIBAVIRIN; RO 5014583; SORAFENIB; T LYMPHOCYTE VACCINE; TELEPRAVIR; UNCLASSIFIED DRUG; VACCINE;

AGE DISTRIBUTION; ANTIVIRAL ACTIVITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG SENSITIVITY; GENOTYPE; HEPATITIS C; HUMAN; NONHUMAN; PHARMACODYNAMICS; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; VIRAL GENETICS; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

EID: 77955521578     PISSN: None     EISSN: 1179139X     Source Type: Book Series    
DOI: None     Document Type: Review

References (76)

1. [No authors listed]. Hepatitis C: Global prevalence (update). Wkly Epidemiol Rec. 1999;74:425-427
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
3. Isaacs A, Lindenmann J, Valentine RC. Virus interference. II. Some properties of interferon. Proc R Soc Lond B Biol Sci. 1957;147:268-273.
4. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461: 798-801.
5. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461: 399-401.
6. Rubinstein M, Rubinstein S, Familletti PC, et al. Human leukocyte interferon: Production, purification to homogeneity, and initial characterization. Proc Natl Acad Sci USA. 1979;76:640-644.
7. Tsuda N, Yuki N, Mochizuki K, et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol. 2004;74:406-413.
8. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347: 975-982.
9. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappa B by Toll-like receptor 3. Nature. 2001;413:732-738.
10. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-1 helicases in the recognition of RNA viruses. Nature. 2006;441: 101-105.
11. Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA. 2002;99:15669-15674.
12. de Veer MJ, Holko M, Frevel M, et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol. 2001;69:912-920.
13. Roberts WK, Hovanessian A, Brown RE, Clemens MJ, Kerr IM. Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis. Nature. 1976;264:477-480.
14. Kerr IM, Brown RE. pppA2'p5'A2'p5'A: An inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc Natl Acad Sci USA. 1978;75:256-260.
15. Arnheiter H, Frese M, Kambadur R, Meier E, Haller O. Mx transgenic mice-animal models of health. Curr Top Microbiol Immunol. 1996;206:119-147.
16. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol. 2001;75:7059-7066.
17. Luft T, Luetjens P, Hochrein H, et al. IFN-alpha enhances CD40 ligandmediated activation of immature monocyte-derived dendritic cells. Int Immunol. 2002;14:367-380.
18. Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon alpha increases the frequency of interferon gamma-producing human CD4..T cells. J Exp Med. 1993;178:1655-1663.
19. Shin EC, Seifert U, Kato T, et al. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest. 2006;116:3006-3014.
20. Pybus OG, Barnes E, Taggart R, et al. Genetic history of hepatitis C virus in East Asia. J Virol. 2009;83:1071-1082.
21. Melen K, Fagerlund R, Nyqvist M, Keskinen P, Julkunen I. Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs. J Med Virol. 2004;73:536-547.
22. Lin W, Kim SS, Yeung E, et al. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol. 2006;80:9226-9235.
23. Bode JG, Ludwig S, Ehrhardt C, et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 2003;17:488-490.
24. de Lucas S, Bartolome J, Carreno V. Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J Infect Dis. 2005;191:93-99.
25. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science. 2003;300:1145-1148.
26. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA. 2005;102:2992-2997.
27. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-1 antiviral pathway and is targeted by hepatitis C virus. Nature. 2005;437:1167-1172.
28. Lau DT, Fish PM, Sinha M, et al. Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology. 2008;47: 799-809.
29. Polyak SJ, Khabar KS, Paschal DM, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol. 2001;75:6095-6106.
30. Polyak SJ, Khabar KS, Rezeiq M, Gretch DR. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol. 2001;75:6209-6211.
31. Gale MJ Jr, Korth MJ, Katze MG. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: A potential mechanism of interferon resistance. Clin Diagn Virol. 1998;10:157-162.
32. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science. 1999;285:107-110.
33. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials. Hepatology. 1997;26:83S-88S.
34. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-1492.
35. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1493-1499.
36. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. J Hepatol. 1996;25:591-598.
37. Cramp ME, Rossol S, Chokshi S, et al. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology. 2000;118:346-355.
38. Barnes E, Salio M, Cerundolo V, et al. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother. 2004;48:3382-3389.
39. Lutchman G, Danehower S, Song BC, et al. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology. 2007;132:1757-1766.
40. Son MJ, Song HS, Kim MH, et al. Synergistic effect and condition of pegylated interferon alpha with paclitaxel on glioblastoma. Int J Oncol. 2006;28:1385-1392.
41. Foster GR. Review article: Pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther. 2004;20:825-830.
42. Santantonio T, Medda E, Ferrari C, et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis. 2006;43:1154-1159.
43. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study. Hepatology. 2006;43:250-256.
44. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet. 2008; 372:321-332.
45. Farci P, Strazzera R, Alter HJ, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA. 2002;99:3081-3086.
46. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 1994;19: 1321-1324.
47. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77-81.
48. Gale M Jr, Blakely CM, Kwieciszewski B, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation. Mol Cell Biol. 1998;18:5208-5218.
49. Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology. 1997;25:740-744.
50. Witherell GW, Beineke P. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol. 2001;63:8-16.
51. Akuta N, Suzuki F, Sezaki H, et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol. 2006;78:83-90.
52. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. J Med Virol. 2010;82:575-582.
53. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426-1432.
54. Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology. 1997;113:558-566.
55. Neumann A, Lam N, Dahari H, et al. HCV Viral dynamics in vivo and the efficacy of Interferon alpha therapy. Science. 1998;282:103-107.
56. Boulestin A, Kamar N, Sandres-Saune K, et al. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. J Med Virol. 2006;78:365-371.
57. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis. 2000;182: 28-35.
58. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.
59. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology. 2008;47:43-50.
60. Berg T, Weich V, Teuber G, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology. 2009;50:369-377.
61. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology. 2004;40:1260-1265.
62. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609-2617.
63. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129:522-527.
64. Yuan Y, Shimizu I, Shen M, et al. Effects of estradiol and progesterone on the proinflammatory cytokine production by mononuclear cells from patients with chronic hepatitis C. World J Gastroenterol. 2008;14:2200-2207.
65. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology. 2000;119:1317-1323.
66. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010;138:2307-2314.
67. Rosen HR, Weston SJ, Im K, et al. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology. 2007;46:350-358.
68. Pilli M, Zerbini A, Penna A, et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology. 2007;133:1132-1143.
69. Barnes E, Gelderblom HC, Humphreys I, et al. Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus Infection. J Infect Dis. 2009;199:819-828.
70. Neumann-Haefelin C, Timm J, Schmidt J, et al. Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8..T-cell epitope. Hepatology. 2010;51:54-62.
71. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genomewide association study. Gastroenterology. 2010;138:1338-1345 e7.
72. Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology. 2008;48:407-417.
73. Novozenov VZ, Vinogradova E, Nikitin I, et al. Phase II study of omega interferon alone or in combination with ribavarin in subjects with chronic hepatitis C genotype 1 infections. J Hepatol. 2007;46:S8.
74. De Leede LG, Humphries JE, Bechet AC, et al. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. J Interferon Cytokine Res. 2008;28:113-122.
75. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827-1838.
76. Sherman KE, Fleischer R, Laessig K, et al. Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations. Hepatology. 2007;46:2014-2020.